The epidemiology and molecular characterstics of hepatitis B virus infection in children from a hyperendemic area of South Africa, including a field trial of the hepatitis B immunization programme and its impact on infection in this population
No Thumbnail Available
Date
2014-04-08
Authors
Vardas, Eftyhia
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Three studies were done in children from the Eastern Cape Province of South Africa,
an area highly endemic for hepatitis B virus (HBV) infection. The objective of the first
study was to investigate the epidemiology and age of acquisition of HBV infection in a
community based, age stratified sample of children from 0-6 years of age (n=2299), to
provide a pre-immunisation baseline measure of this infection in the population
targeted for HBV immunisation in South Africa. The results suggest that there is a
significant burden of HBV infection in the population targeted for immunisation (overall,
10.4% HBsAg positivity and 15.7% positive 61-72 month age group) with a high rate
of chronic carriers in the early age groups of 0-6 (8.1%) and 7-12 (8.9%) months.
In the second study the HBV genotypes in a randomly selected group of chronically
infected individuals from the same population (n=57) was determined. The aim was to
supply information regarding the naturally circulating HBV genotypes in children from
this area similarly, to provide baseline information to enable the future detection of
escape mutants after low dose HBV immunisation had been introduced. The
predominant HBV genotype identified was A' (85.7%), genotype D was found in 11.4%
and A in 2.9% of the amplified specimens. These findings suggest a unique circulation
of HBV genotypes in the Eastern Cape compared to the other genotypes currently
identified in South Africa.
In the final study, the effectiveness under field conditions of a low-dose plasma derived
(LDPD) HBV vaccine chosen for the EPI programme in South Africa was assessed.
Children presenting for routine immunisations at 6 weeks of age were randomly
assigned to receive either LDPD HBV vaccine through the normal clinic route (n=119)
or a recombinant paediatric HBV vaccine (n=108) given under controlled conditions.
Both vaccines were administered at 6 ,1 0 and 14 weeks of age. At one month after the
last vaccination, LDPD vaccine induced levels of anti-HBs s 10 mlU/ml in 42.2% (95%
Cl 27.99-57.77) of immunised infants whereas recombinant vaccine induced protective
antibody levels in 88.6% (95% Cl 74.66-95.74) of immunised infants. These results
suggest a poor performance of the LDPD vaccine under field conditions in Eastern
Cape infants.